Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-21822 in Combination With JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
NCT05288205Phase 2Recruiting
- Sponsor
- Allist Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of glecirasib, sitneprotafib in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), sponsored by Allist Pharmaceuticals. Started Apr 2022; status: recruiting.
02
Drugs
glecirasibsitneprotafib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05288205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05288205.